---
document_datetime: 2025-11-23 14:34:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/nevirapine-teva.html
document_name: nevirapine-teva.html
version: success
processing_time: 0.1048888
conversion_datetime: 2025-12-26 12:45:34.792233
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Nevirapine Teva

[RSS](/en/individual-human-medicine.xml/65786)

##### Withdrawn

This medicine's authorisation has been withdrawn

nevirapine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Nevirapine Teva](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 6 March 2023 the European Commission withdrew the marketing authorisation for Nevirapine Teva (nevirapine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Nevirapine Teva was granted marketing authorisation in the EU on 30 November 2009 for treatment of HIV-1 infection. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2014. Nevirapine Teva is a generic medicine of Viramune.

The European Public Assessment Report (EPAR) for Nevirapine Teva is updated to indicate that the marketing authorisation is no longer valid.

Nevirapine Teva : EPAR - Summary for the public

English (EN) (653.78 KB - PDF)

**First published:** 14/12/2009

**Last updated:** 21/03/2023

[View](/en/documents/overview/nevirapine-teva-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-215)

български (BG) (724.99 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/bg/documents/overview/nevirapine-teva-epar-summary-public_bg.pdf)

español (ES) (652.55 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/es/documents/overview/nevirapine-teva-epar-summary-public_es.pdf)

čeština (CS) (708.6 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/cs/documents/overview/nevirapine-teva-epar-summary-public_cs.pdf)

dansk (DA) (652.18 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/da/documents/overview/nevirapine-teva-epar-summary-public_da.pdf)

Deutsch (DE) (656.96 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/de/documents/overview/nevirapine-teva-epar-summary-public_de.pdf)

eesti keel (ET) (651.72 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/et/documents/overview/nevirapine-teva-epar-summary-public_et.pdf)

ελληνικά (EL) (726.6 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/el/documents/overview/nevirapine-teva-epar-summary-public_el.pdf)

français (FR) (652.99 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fr/documents/overview/nevirapine-teva-epar-summary-public_fr.pdf)

hrvatski (HR) (668.94 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hr/documents/overview/nevirapine-teva-epar-summary-public_hr.pdf)

italiano (IT) (651.97 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/it/documents/overview/nevirapine-teva-epar-summary-public_it.pdf)

latviešu valoda (LV) (709.06 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lv/documents/overview/nevirapine-teva-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (675.28 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lt/documents/overview/nevirapine-teva-epar-summary-public_lt.pdf)

magyar (HU) (705.31 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hu/documents/overview/nevirapine-teva-epar-summary-public_hu.pdf)

Malti (MT) (711.01 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/mt/documents/overview/nevirapine-teva-epar-summary-public_mt.pdf)

Nederlands (NL) (655.91 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/nl/documents/overview/nevirapine-teva-epar-summary-public_nl.pdf)

polski (PL) (728.36 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pl/documents/overview/nevirapine-teva-epar-summary-public_pl.pdf)

português (PT) (653.35 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pt/documents/overview/nevirapine-teva-epar-summary-public_pt.pdf)

română (RO) (675.02 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/ro/documents/overview/nevirapine-teva-epar-summary-public_ro.pdf)

slovenčina (SK) (732.71 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sk/documents/overview/nevirapine-teva-epar-summary-public_sk.pdf)

slovenščina (SL) (697.89 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sl/documents/overview/nevirapine-teva-epar-summary-public_sl.pdf)

Suomi (FI) (651.53 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fi/documents/overview/nevirapine-teva-epar-summary-public_fi.pdf)

svenska (SV) (652.32 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sv/documents/overview/nevirapine-teva-epar-summary-public_sv.pdf)

## Product information

Nevirapine Teva : EPAR - Product Information

English (EN) (1.28 MB - PDF)

**First published:** 14/12/2009

**Last updated:** 21/03/2023

[View](/en/documents/product-information/nevirapine-teva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-588)

български (BG) (2.5 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/bg/documents/product-information/nevirapine-teva-epar-product-information_bg.pdf)

español (ES) (1.36 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/es/documents/product-information/nevirapine-teva-epar-product-information_es.pdf)

čeština (CS) (2.18 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/cs/documents/product-information/nevirapine-teva-epar-product-information_cs.pdf)

dansk (DA) (1.31 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/da/documents/product-information/nevirapine-teva-epar-product-information_da.pdf)

Deutsch (DE) (1.36 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/de/documents/product-information/nevirapine-teva-epar-product-information_de.pdf)

eesti keel (ET) (1.27 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/et/documents/product-information/nevirapine-teva-epar-product-information_et.pdf)

ελληνικά (EL) (2.6 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/el/documents/product-information/nevirapine-teva-epar-product-information_el.pdf)

français (FR) (1.34 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fr/documents/product-information/nevirapine-teva-epar-product-information_fr.pdf)

hrvatski (HR) (1.48 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hr/documents/product-information/nevirapine-teva-epar-product-information_hr.pdf)

íslenska (IS) (1.3 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/is/documents/product-information/nevirapine-teva-epar-product-information_is.pdf)

italiano (IT) (1.33 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/it/documents/product-information/nevirapine-teva-epar-product-information_it.pdf)

latviešu valoda (LV) (2.21 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lv/documents/product-information/nevirapine-teva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.39 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lt/documents/product-information/nevirapine-teva-epar-product-information_lt.pdf)

magyar (HU) (2.13 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hu/documents/product-information/nevirapine-teva-epar-product-information_hu.pdf)

Malti (MT) (2.21 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/mt/documents/product-information/nevirapine-teva-epar-product-information_mt.pdf)

Nederlands (NL) (1.33 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/nl/documents/product-information/nevirapine-teva-epar-product-information_nl.pdf)

norsk (NO) (1.27 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/no/documents/product-information/nevirapine-teva-epar-product-information_no.pdf)

polski (PL) (2.16 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pl/documents/product-information/nevirapine-teva-epar-product-information_pl.pdf)

português (PT) (1.29 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pt/documents/product-information/nevirapine-teva-epar-product-information_pt.pdf)

română (RO) (1.45 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/ro/documents/product-information/nevirapine-teva-epar-product-information_ro.pdf)

slovenčina (SK) (2.25 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sk/documents/product-information/nevirapine-teva-epar-product-information_sk.pdf)

slovenščina (SL) (2.1 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sl/documents/product-information/nevirapine-teva-epar-product-information_sl.pdf)

Suomi (FI) (1.3 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fi/documents/product-information/nevirapine-teva-epar-product-information_fi.pdf)

svenska (SV) (1.3 MB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sv/documents/product-information/nevirapine-teva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0024 08/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Nevirapine Teva : EPAR - All Authorised presentations

English (EN) (592.65 KB - PDF)

**First published:** 14/12/2009

**Last updated:** 21/03/2023

[View](/en/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-384)

български (BG) (651.93 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/bg/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_bg.pdf)

español (ES) (593.81 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/es/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (643.85 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/cs/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (587.91 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/da/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (587.17 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/de/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (587.95 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/et/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (649.7 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/el/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_el.pdf)

français (FR) (589.66 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fr/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (672.48 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hr/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (588.89 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/is/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (588.68 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/it/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (637.94 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lv/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (660.46 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/lt/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (618.08 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/hu/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (635.03 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/mt/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (588.5 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/nl/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (593.6 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/no/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_no.pdf)

polski (PL) (639.36 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pl/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_pl.pdf)

português (PT) (589.53 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/pt/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_pt.pdf)

română (RO) (623.07 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/ro/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (671.74 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sk/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (638.86 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sl/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (592.5 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/fi/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (591.92 KB - PDF)

**First published:**

14/12/2009

**Last updated:**

21/03/2023

[View](/sv/documents/all-authorised-presentations/nevirapine-teva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Nevirapine Teva Active substance nevirapine International non-proprietary name (INN) or common name nevirapine Therapeutic area (MeSH) HIV Infections Anatomical therapeutic chemical (ATC) code J05AG01

### Pharmacotherapeutic group

Antivirals for systemic use

### Therapeutic indication

Nevirapine Teva is indicated in combination with other anti-retroviral medicinal products for the treatment of HIV 1 infected adults, adolescents, and children of any age.

Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing.

## Authorisation details

EMA product number EMEA/H/C/001119

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Teva B.V.

Teva B.V.

Opinion adopted 24/09/2009 Marketing authorisation issued 30/11/2009 Revision 11

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Nevirapine Teva : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (747.69 KB - PDF)

**First published:** 26/07/2011

**Last updated:** 21/03/2023

[View](/en/documents/procedural-steps-after/nevirapine-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Nevirapine Teva : EPAR - Public assessment report

English (EN) (840.3 KB - PDF)

**First published:** 14/12/2009

**Last updated:** 21/03/2023

[View](/en/documents/assessment-report/nevirapine-teva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Nevirapine Teva

Reference Number: EMEA/CHMP/578510/2009

English (EN) (605.24 KB - PDF)

**First published:** 24/09/2009

**Last updated:** 21/03/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-nevirapine-teva_en.pdf)

#### News on Nevirapine Teva

[Ranbaxy, Toansa assessment concluded: no risk to public health](/en/news/ranbaxy-toansa-assessment-concluded-no-risk-public-health) 05/06/2014

**This page was last updated on** 21/03/2023

## Share this page

[Back to top](#main-content)